Matches in SemOpenAlex for { <https://semopenalex.org/work/W181493225> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W181493225 abstract "L-dopa is the most effective treatment for Parkinson’s disease (PD). Although L-dopa improves PD symptoms in the initial stages of the disease, its long-term use causes disabling side effects (dyskinesias) consisting of abnormal involuntary movements (AIMs). Recent studies point to endocannabinoid system as an important modulator of dopamine transmission in the basal ganglia and activation of cannabinoid receptors is emerging as a promising therapy to alleviate L-dopa-induced dyskinesias. 6-OHDA-lesioned rats chronically treated (12 days) with L-dopa (6mg/kg, plus carbidopa, 12 mg/kg, i.p.) develop increasingly severe axial, limb, locomotor and orofacial AIMs. Administration of the cannabinoid agonist WIN 55,212-2 (WIN, 1mg/kg, i.p.) significantly attenuated L-Dopa-induced AIMs. The antidiskynetic effect of WIN was reversed by the CB1 antagonist AM251 (1mg/kg, i.p), and was not due to a generalized motor suppression, as the dose used had no effect on behavioral measures of catalepsy and locomotor activity. Systemic administration of URB597 (0.3mg/kg, i.p.), a potent FAAH inhibitor, had no effect on AIMs scoring although it significantly elevated anandamide throughout the basal ganglia of lesioned rats. Unlike WIN, anandamide can activate TRPV1 receptors, which have been implicated in the regulation of basal ganglia functions. Interestingly, subchronic co-administration of URB597 and capsazepine (10mg/kg), a selective TRPV1 antagonist, significantly decreased all L-dopa-induced AIMs subtypes, whereas capsazepine had no effect when administered alone. Our data suggest that CB1 and TRPV1 receptors play opposite roles in levodopa-induced dyskinesias. Supported by NIH - NS 050401 (A.G.)." @default.
- W181493225 created "2016-06-24" @default.
- W181493225 creator A5019816959 @default.
- W181493225 creator A5036218513 @default.
- W181493225 date "2007-01-01" @default.
- W181493225 modified "2023-10-16" @default.
- W181493225 title "Direct and indirect cannabinoid agonists reduce L‐dopa‐induced‐dyskinesias via CB1‐ and TRPV1‐mediated mechanisms" @default.
- W181493225 doi "https://doi.org/10.1096/fasebj.21.6.a787-b" @default.
- W181493225 hasPublicationYear "2007" @default.
- W181493225 type Work @default.
- W181493225 sameAs 181493225 @default.
- W181493225 citedByCount "0" @default.
- W181493225 crossrefType "journal-article" @default.
- W181493225 hasAuthorship W181493225A5019816959 @default.
- W181493225 hasAuthorship W181493225A5036218513 @default.
- W181493225 hasConcept C126322002 @default.
- W181493225 hasConcept C134018914 @default.
- W181493225 hasConcept C148001335 @default.
- W181493225 hasConcept C155164980 @default.
- W181493225 hasConcept C160145004 @default.
- W181493225 hasConcept C170493617 @default.
- W181493225 hasConcept C185592680 @default.
- W181493225 hasConcept C2776158853 @default.
- W181493225 hasConcept C2776433454 @default.
- W181493225 hasConcept C2778938600 @default.
- W181493225 hasConcept C2779134260 @default.
- W181493225 hasConcept C2779734285 @default.
- W181493225 hasConcept C2779783865 @default.
- W181493225 hasConcept C2780071552 @default.
- W181493225 hasConcept C2780871563 @default.
- W181493225 hasConcept C46721173 @default.
- W181493225 hasConcept C71924100 @default.
- W181493225 hasConcept C98274493 @default.
- W181493225 hasConceptScore W181493225C126322002 @default.
- W181493225 hasConceptScore W181493225C134018914 @default.
- W181493225 hasConceptScore W181493225C148001335 @default.
- W181493225 hasConceptScore W181493225C155164980 @default.
- W181493225 hasConceptScore W181493225C160145004 @default.
- W181493225 hasConceptScore W181493225C170493617 @default.
- W181493225 hasConceptScore W181493225C185592680 @default.
- W181493225 hasConceptScore W181493225C2776158853 @default.
- W181493225 hasConceptScore W181493225C2776433454 @default.
- W181493225 hasConceptScore W181493225C2778938600 @default.
- W181493225 hasConceptScore W181493225C2779134260 @default.
- W181493225 hasConceptScore W181493225C2779734285 @default.
- W181493225 hasConceptScore W181493225C2779783865 @default.
- W181493225 hasConceptScore W181493225C2780071552 @default.
- W181493225 hasConceptScore W181493225C2780871563 @default.
- W181493225 hasConceptScore W181493225C46721173 @default.
- W181493225 hasConceptScore W181493225C71924100 @default.
- W181493225 hasConceptScore W181493225C98274493 @default.
- W181493225 hasFunder F4320332161 @default.
- W181493225 hasIssue "6" @default.
- W181493225 hasLocation W1814932251 @default.
- W181493225 hasOpenAccess W181493225 @default.
- W181493225 hasPrimaryLocation W1814932251 @default.
- W181493225 hasRelatedWork W181493225 @default.
- W181493225 hasRelatedWork W1988795372 @default.
- W181493225 hasRelatedWork W2015830587 @default.
- W181493225 hasRelatedWork W2022279968 @default.
- W181493225 hasRelatedWork W2057944138 @default.
- W181493225 hasRelatedWork W2068344771 @default.
- W181493225 hasRelatedWork W2132907653 @default.
- W181493225 hasRelatedWork W2951374929 @default.
- W181493225 hasRelatedWork W4210645529 @default.
- W181493225 hasRelatedWork W4295292804 @default.
- W181493225 hasVolume "21" @default.
- W181493225 isParatext "false" @default.
- W181493225 isRetracted "false" @default.
- W181493225 magId "181493225" @default.
- W181493225 workType "article" @default.